Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Receivables: 2020-2023

Historic Change in Receivables for Immuneering (IMRX) over the last 2 years, with Jun 2023 value amounting to -$1,046.

  • Immuneering's Change in Receivables rose 98.97% to -$1,046 in Q2 2023 from the same period last year, while for Jun 2023 it was -$178,425, marking a year-over-year increase of 47.88%. This contributed to the annual value of -$12,417 for FY2023, which is 94.69% up from last year.
  • According to the latest figures from Q2 2023, Immuneering's Change in Receivables is -$1,046, which was up 90.80% from -$11,371 recorded in Q1 2023.
  • In the past 5 years, Immuneering's Change in Receivables ranged from a high of $278,185 in Q3 2020 and a low of -$250,978 during Q4 2021.
  • Its 3-year average for Change in Receivables is -$52,575, with a median of -$17,550 in 2021.
  • Data for Immuneering's Change in Receivables shows a peak YoY increase of 535.73% (in 2022) and a maximum YoY decrease of 3,847.70% (in 2022) over the last 5 years.
  • Quarterly analysis of 4 years shows Immuneering's Change in Receivables stood at -$78,035 in 2020, then plummeted by 221.62% to -$250,978 in 2021, then skyrocketed by 76.98% to -$57,763 in 2022, then soared by 98.97% to -$1,046 in 2023.
  • Its last three reported values are -$1,046 in Q2 2023, -$11,371 for Q1 2023, and -$57,763 during Q4 2022.